Loading...
Hyloris Pharmaceuticals SA
HYL.BR•EURONEXT
Healthcare
Biotechnology
€4.85
€-0.25(-4.90%)
U.S. Market opens in 55h 47mHyloris Pharmaceuticals SA (HYL.BR) AI-Powered Stock Analysis
See how Hyloris Pharmaceuticals SA scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerHyloris Pharmaceuticals SA (HYL.BR) Stock Overall Grade
Hyloris Pharmaceuticals SA’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Hyloris Pharmaceuticals SA's overall stock rating.
Forecast
C+Score
56/100Financial Growth
A+Score
100/100Fundamental Growth
CScore
48/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Hyloris Pharmaceuticals SA (HYL.BR) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (100/100, A+) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Hyloris Pharmaceuticals SA stock grade, including financials, comparisons, and forecasts.